Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of RNA-modulating drugs in the United States. The company develops ELX-02, which is in phase II clinical trial for the treatment of nonsense mutation alport syndrome; ZKN013, which is in investigation phase for the treatment of nonsense mutation recessive dystrophic and junctional epidermolysis bullosa; and ZKN013, which is in investigation phase for the treatment of nonsense mutation familial adenomatous polyposis. It also offers platform technologies, including Turbo-ZM and Ribosome Modulating Agents; and Eukaryotic Ribosomal Selective Glycosides for the treatment of rare and ultra-rare premature stop codon diseases. The company is headquartered in Watertown, Massachusetts.